Search research articles
Contact Us
Filters
Showing results (771-780 of 818) with videos related to
Page
of 82
Sort By:
Oncoimmunology
|
August 17, 2017
Mapping the human T cell repertoire to recurrent driver mutations in MYD88 and EZH2 in lymphoma
Julie S Nielsen, Andrew R Chang, Darin A Wick, et al.
JCO Precision Oncology
|
November 6, 2020
Prospective Multicenter Study of Circulating Tumor Cell AR-V7 and Taxane Versus Hormonal Treatment Outcomes in Metastatic Castration-Resistant Prostate Cancer
Andrew J Armstrong, Jun Luo, David M Nanus, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics
|
June 3, 2022
Reclassification of clinically-detected sequence variants: Framework for genetic clinicians and clinical scientists by CanVIG-UK (Cancer Variant Interpretation Group UK)
Lucy Loong, Alice Garrett, Sophie Allen, et al.
JAMA Oncology
|
May 8, 2020
Effect of Combined Immune Checkpoint Inhibition vs Best Supportive Care Alone in Patients With Advanced Colorectal Cancer: The Canadian Cancer Trials Group CO.26 Study
Eric X Chen, Derek J Jonker, Jonathan M Loree, et al.
European Urology Oncology
|
November 8, 2023
Pembrolizumab and Enzalutamide in Patients with Abiraterone Acetate-Pretreated Metastatic Castration-Resistant Prostate Cancer: Cohort C of the Phase 1b/2 KEYNOTE-365 Study
Evan Y Yu, William R Berry, Howard Gurney, et al.
Journal of Medicinal Chemistry
|
December 20, 1996
Indole inhibitors of human nonpancreatic secretory phospholipase A2. 3. Indole-3-glyoxamides
S E Draheim, N J Bach, R D Dillard, et al.
Journal of Medicinal Chemistry
|
December 20, 1996
Indole inhibitors of human nonpancreatic secretory phospholipase A2. 2. Indole-3-acetamides with additional functionality
R D Dillard, N J Bach, S E Draheim, et al.
European Urology
|
April 10, 2022
Pembrolizumab Plus Docetaxel and Prednisone in Patients with Metastatic Castration-resistant Prostate Cancer: Long-term Results from the Phase 1b/2 KEYNOTE-365 Cohort B Study
Evan Y Yu, Michael P Kolinsky, William R Berry, et al.
Journal of Medicinal Chemistry
|
December 20, 1996
Indole inhibitors of human nonpancreatic secretory phospholipase A2. 1. Indole-3-acetamides
R D Dillard, N J Bach, S E Draheim, et al.
Familial Cancer
|
July 10, 2012
Clinical correlation and molecular evaluation confirm that the MLH1 p.Arg182Gly (c.544A>G) mutation is pathogenic and causes Lynch syndrome
Michael P Farrell, David J Hughes, Ian R Berry, et al.
Page
of 82
Search research articles
Search
Showing results (771-780 of 818) with videos related to
Sort By:
Page
of 82
Oncoimmunology
|
August 17, 2017
Mapping the human T cell repertoire to recurrent driver mutations in MYD88 and EZH2 in lymphoma
Julie S Nielsen, Andrew R Chang, Darin A Wick, et al.
JCO Precision Oncology
|
November 6, 2020
Prospective Multicenter Study of Circulating Tumor Cell AR-V7 and Taxane Versus Hormonal Treatment Outcomes in Metastatic Castration-Resistant Prostate Cancer
Andrew J Armstrong, Jun Luo, David M Nanus, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics
|
June 3, 2022
Reclassification of clinically-detected sequence variants: Framework for genetic clinicians and clinical scientists by CanVIG-UK (Cancer Variant Interpretation Group UK)
Lucy Loong, Alice Garrett, Sophie Allen, et al.
JAMA Oncology
|
May 8, 2020
Effect of Combined Immune Checkpoint Inhibition vs Best Supportive Care Alone in Patients With Advanced Colorectal Cancer: The Canadian Cancer Trials Group CO.26 Study
Eric X Chen, Derek J Jonker, Jonathan M Loree, et al.
European Urology Oncology
|
November 8, 2023
Pembrolizumab and Enzalutamide in Patients with Abiraterone Acetate-Pretreated Metastatic Castration-Resistant Prostate Cancer: Cohort C of the Phase 1b/2 KEYNOTE-365 Study
Evan Y Yu, William R Berry, Howard Gurney, et al.
Journal of Medicinal Chemistry
|
December 20, 1996
Indole inhibitors of human nonpancreatic secretory phospholipase A2. 3. Indole-3-glyoxamides
S E Draheim, N J Bach, R D Dillard, et al.
Journal of Medicinal Chemistry
|
December 20, 1996
Indole inhibitors of human nonpancreatic secretory phospholipase A2. 2. Indole-3-acetamides with additional functionality
R D Dillard, N J Bach, S E Draheim, et al.
European Urology
|
April 10, 2022
Pembrolizumab Plus Docetaxel and Prednisone in Patients with Metastatic Castration-resistant Prostate Cancer: Long-term Results from the Phase 1b/2 KEYNOTE-365 Cohort B Study
Evan Y Yu, Michael P Kolinsky, William R Berry, et al.
Journal of Medicinal Chemistry
|
December 20, 1996
Indole inhibitors of human nonpancreatic secretory phospholipase A2. 1. Indole-3-acetamides
R D Dillard, N J Bach, S E Draheim, et al.
Familial Cancer
|
July 10, 2012
Clinical correlation and molecular evaluation confirm that the MLH1 p.Arg182Gly (c.544A>G) mutation is pathogenic and causes Lynch syndrome
Michael P Farrell, David J Hughes, Ian R Berry, et al.
Page
of 82